首页|血液灌流联合连续性血液透析在急性有机磷中毒患者中的应用效果分析

血液灌流联合连续性血液透析在急性有机磷中毒患者中的应用效果分析

扫码查看
目的 观察血液灌流(HP)联合血液透析对急性有机磷中毒(AOPP)患者胆碱酯酶(ChE)活性及炎症因子水平的影响.方法 采用回顾性队列研究方法.选择 2020 年 1 月至 2022 年 12 月入住颍上县人民医院急诊科的 73 例AOPP患者作为研究对象.按治疗方案不同将患者分为HP组(31 例)和HP+连续性肾脏替代治疗(CRRT)组(42 例).所有患者入科后均按照标准方案给予对症支持治疗.HP组患者入科后尽早给予HP治疗,治疗时间为 2~3 h,间隔 24h进行 1 次;HP+CRRT组患者于HP结束后进行连续性静脉-静脉血液透析滤过(CVVHDF).比较两组患者入科后(T0)、第 1 次HP/HP+CRRT结束时(T1)、第 2 次HP/HP+CRRT结束时(T2)、第 3 次HP/HP+CRRT结束时(T3)血清ChE、肿瘤坏死因子-α(TNF-α)、白细胞介素(IL-1、IL-6)水平,以及ChE恢复时间、中间综合征(IMS)发生率、住院时间、入住ICU率等的差异.结果 随治疗时间延长,两组治疗后T1、T2、T3 时ChE活性均较T0 时间明显增加,TNF-α、IL-1、IL-6 水平均较T0 时间明显降低,T3 时达到谷值,且以HP+CRRT组的变化较HP组更显著[ChE活性(U/L):2 903.26±164.43 比2292.98±350.96,TNF-α(ng/L):78.24±10.75 比 100.55±15.58,IL-1(ng/L):95.98±22.56 比 127.94±18.74,IL-6(ng/L):34.36±8.66 比 58.74±10.46,均P<0.05].HP+CRRT组ChE活性恢复时间、住院时间均较HP组明显缩短[ChE活性恢复时间(d):4.42±1.17 比 7.31±1.46,住院时间(d):9.25±2.14 比 12.75±2.30,均P<0.05],IMS发生率和入住ICU率均较HP组明显降低[IMS发生率:33.33%(14/42)比61.29%(19/31),入住ICU率:9.52%(4/42)比 29.03%(9/31),均P<0.05].结论 对于AOPP患者,HP+CRRT在炎症因子清除、恢复ChE活性时间、降低IMS发生率、缩短住院时间等方面均优于单纯HP治疗,可在临床推广应用.
Analysis of the application effect of hemoperfusion combined with continuous hemodialysis in patients with acute organophosphorus pesticide poisoning
Objective To observe the effects of hemoperfusion(HP)combined with hemodialysis on cholinesterase(ChE)activity and inflammatory factors in patients with acute organophosphorus pesticide poisoning(AOPP).Methods A retrospective cohort study was conducted.Seventy-three AOPP patients admitted to the department of emergency of Yingshang People's Hospital from January 2020 to December 2022 were enrolled.The patients were divided into HP group(31 cases)and HP+continuous renal replacement therapy(CRRT)group(42 cases)according to different treatment regimens.All patients were given supportive treatment according to the standard protocol after admission.HP was given to the patients as soon as possible after admission,and the treatment time was between 2 hours and 3 hours,with an interval of 24 hours.Patients in HP+CRRT group were treated with continuous veno-venous hemodiafiltration(CVVHDF)after HP.The serum ChE,tumor necrosis factor-α(TNF-α),and interleukins(IL-1,IL-6)levels were compared between the two groups after admission(T0),at the end of the first HP/HP+CRRT(T1),at the end of the second HP/HP+CRRT(T2),and at the end of the third HP/HP+CRRT(T3).The ChE recovery time,the incidence of intermediate syndrome(IMS),the length of hospital stay,and the rate of admission to ICU were also compared.Results With the extension of treatment time,the ChE activity at T1,T2,and T3 in the two groups was significantly higher than that at T0,and the levels of TNF-α,IL-1,and IL-6 were significantly lower than those at T0,reaching the trough value at T3,and the changes in HP+CRRT group were more significant than those in HP group[ChE activity(U/L):2 903.26±164.43 vs.2 292.98±350.96,TNF-α(ng/L):78.24±10.75 vs.100.55±15.58,IL-1(ng/L):95.98±22.56 vs.127.94±18.74,IL-6(ng/L):34.36±8.66 vs.58.74±10.46,all P<0.05].The recovery time of ChE activity and length of hospital stay in HP+CRRT group were significantly shorter than those in HP group[ChE activity recovery time(days):4.42±1.17 vs.7.31±1.46,length of hospital stay(days):9.25±2.14 vs.12.75±2.30,both P<0.05],the incidence of IMS and ICU admission rate were significantly lower than those in HP group[the incidence of IMS:33.33%(14/42)vs.61.29%(19/31),ICU admission rate:9.52%(4/42)vs.29.03%(9/31),both P<0.05].Conclusion For AOPP patients,HP+CRRT is superior to HP alone in the clearance of inflammatory factors,restoring ChE activity,reducing the incidence of IMS,and shortening the length of hospital stay,making it a valuable option for clinical application.

HemoperfusionContinuous renal replacement therapyAcute organophosphorus pesticide poisoningAnalysis of efficacy

穆士伟、王鑫、刘玲、张鹏、花砚、汤永

展开 >

颍上县人民医院急诊科,安徽阜阳 236200

皖南医学院弋矶山医院重症医学科,安徽芜湖 241000

血液灌流 连续性肾脏替代治疗 急性有机磷中毒 疗效分析

安徽省医疗卫生重点专科建设项目安徽省阜阳市卫生健康委科研项目

2021-273FY2021-088

2024

中国中西医结合急救杂志
中国中西医结合学会

中国中西医结合急救杂志

CSTPCD
影响因子:1.925
ISSN:1008-9691
年,卷(期):2024.31(1)
  • 23